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Background: Current International Diabetes Federation guidelines recommend a target HbA1c <7.0%, but many
people with diabetes worldwide find this difficult to achieve, increasing their risk of developing complications. This
publication examines the prevalence of diabetes complications and its association with baseline characteristics in
people with type 2 diabetes who participated in the A1chieve study.
Methods: A1chieve was a 24-week, multinational, open-label, observational study of 66,726 people with type 2
diabetes who had begun using biphasic insulin aspart 30, insulin aspart, or insulin detemir in routine clinical care.
Participants were enrolled from 28 countries across four continents (Asia, Africa, Europe and South America).
Baseline measurements of disease characteristics included: glycated haemoglobin (HbA1c), fasting (FPG) and
post-prandial plasma glucose (PPG), high- and low-density lipoprotein cholesterol (H- or LDL-C), systolic blood
pressure (SBP), and body mass index (BMI). Data on complications and use of vascular disease preventative drugs
were collected.
Results: Complication rates were high (27.2% had macrovascular complications and 53.5% had microvascular
complications), particularly in Russia, and use of vascular disease preventative drugs was lower than expected. Age,
BMI, diabetes duration, LDL-C, and SBP were positively associated, and HDL-C negatively associated, with macro- and
microvascular complications (all p < 0.05). HbA1c and FPG were negatively associated with macrovascular complications
(both p < 0.05), which may be linked to the cross-sectional study design.
Conclusions: These results suggest a worldwide failure to achieve glycaemic targets. Better diabetes management
with earlier initiation and optimisation of insulin regimens (e.g., with insulin analogues in the A1chieve population) may
reduce the prevalence of vascular complications, improve the lives of people with diabetes and reduce the burden on
healthcare systems.
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Effective management of diabetes requires sustained gly-
caemic control over many years to lower the risk of
macro- and microvascular complications in people with
diabetes. The UK Prospective Diabetes Study (UKPDS)
found that every 1% reduction in glycated haemoglobin* Correspondence: leon.litwak@hospitalitaliano.org.ar
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reproduction in any medium, provided the or(HbA1c) was associated with a 37% decrease in micro-
vascular disease and a 14% reduction in myocardial in-
farction (MI) [1]. Results of a 10-year follow-up study
found that people with type 2 diabetes who maintain
good glycaemic control experience benefits many years
later, including lower rates of MI and diabetes-related
death [2].
Accordingly, International Diabetes Federation (IDF)
and joint American Diabetes Association (ADA)/European
Association for the Study of Diabetes (EASD) guidanceLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lines highlight the need to review and to modify therapy
regimens when HbA1c goals can no longer be maintained
[4,5], which may include initiation and intensification of
insulin therapy. Current diabetes guidelines also empha-
sise that cardiovascular disease risk reduction should be a
focus of therapy [4-6]. However, most people with diabetes
find it difficult to achieve HbA1c levels <7.0% [7-10],
with <40% of people with diabetes in a USA national
survey reaching this target [9]. Moreover, in developing
regions, including Eastern Europe, Asia, Latin America,
and Africa, it has been shown that 22% and 36% of people
with type 1 diabetes and type 2 diabetes, respectively, have
never had their HbA1c measured, and of those with avail-
able HbA1c values, only 25% of people with type 1 diabetes
and 36% of people with type 2 diabetes had HbA1c levels
<7.0% [11]. This may increase the likelihood of progres-
sion of diabetes complications and of developing compli-
cations in later life. Reasons for the difficulty in achieving
target HbA1c levels may include problems adhering to
complex oral and injectable therapies, concerns about in-
sulin tolerability, psychological insulin resistance, fears
about the risk of hypoglycaemia, and weight gain after in-
sulin initiation [12-16].
More data are needed to evaluate glycaemic control
and guideline adherence by physicians in real-life clinical
practice in different geographical regions. These data
can be used to assess whether glycaemic control, or any
other factors, predict the establishment of diabetes-
related complications in various ethnic groups.
A1chieve was a multinational, open-label, observational
study of people with type 2 diabetes to assess clinical
safety and effectiveness of biphasic insulin aspart 30
(NovoMix® 30), insulin aspart (NovoRapid®), or insulin
detemir (Levemir®) with or without oral glucose-lowering
drugs (OGLDs) in routine clinical care [17]. Participants
were enrolled from 28 countries in Asia, Africa, South
America and Europe [17]. In this report, diabetes compli-
cations data at baseline were assessed by geographical re-
gion and the relationship of these complications to other
variables (e.g., patient and disease characteristics) was
assessed by correlation analyses.
Methods
This was a 24-week international prospective, multi-
centre, open-label, non-interventional study in people
with type 2 diabetes mellitus who had started biphasic
insulin aspart 30, basal insulin detemir or bolus insulin
aspart. These study drugs could be given alone or in
combination with other medications that the partici-
pants were already taking. Baseline data, before partici-
pants received any of these insulin analogues or within
4 weeks of receiving insulin analogues, are reported in
this analysis. Participants were evaluated by generalphysicians or diabetes specialists at the baseline visit, an
interim visit approximately 12 weeks after the baseline
visit, and a final visit approximately 24 weeks after the
baseline visit.
The participants were enrolled in the study between
January 2009 and June 2010. The 28 countries were
grouped into seven geographical regions: China; South Asia
(Bangladesh, India, and Pakistan); East Asia (Indonesia,
Korea, Malaysia, Philippines, Singapore, and Taiwan);
North Africa (Algeria, Morocco, Tunisia, and Libya);
Middle East/Gulf (Egypt, Iran, Jordan, Turkey, Bahrain,
Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates,
and Yemen); South America (Argentina and Mexico); and
Europe (Russia).
Inclusion and exclusion criteria were kept to a mini-
mum in order to reflect routine clinical practice as closely
as possible. Selection of patients and choice of insulin
regimen were at the discretion of the physician based on
their clinical judgement. Exclusion criteria were: patients
treated with biphasic insulin aspart 30, insulin detemir or
insulin aspart (alone or in combination) for more than
4 weeks before enrolment in the study; patients previously
enrolled in the study; patients with hypersensitivity to bi-
phasic insulin aspart 30, insulin detemir or insulin aspart
or to any of its excipients; and women who were pregnant,
breast-feeding or had the intention of becoming pregnant
within the next six months.
All local requirements for Health Authorities and Eth-
ics Committee approvals were obtained, if applicable.
The study was conducted in accordance with the Declar-
ation of Helsinki [18] and the Guidelines for Good
Pharmacoepidemiology Practice [19].
Assessments
Only baseline measurements are reported in this publi-
cation, which included patient characteristics, disease
characteristics (metabolic control), diabetic macro- and
microvascular complications, and use of vascular disease
preventative drugs. These data were tabulated by total
study population and by geographical region.
Patient characteristics assessed at baseline included:
age, sex, diabetes duration, and body mass index (BMI).
Disease-related characteristics assessed at baseline in-
cluded: HbA1c, fasting plasma glucose (FPG) before
breakfast, post-prandial plasma glucose (PPG) after
breakfast, total cholesterol (TC), triglycerides (TG), cre-
atinine, high-density lipoprotein cholesterol (HDL-C),
low-density lipoprotein cholesterol (LDL-C), systolic
blood pressure (SBP), and quality of life (QoL). QoL
was assessed using the standardised EQ-5D™ where
100 = best imaginable health and 0 = worst imaginable
health [20].
Since this is an open label, observational study, all
complications data were collected from available medical
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ments performed. Data were collected for the following
macrovascular complications based on the physician’s
clinical judgement: MI, angina, peripheral vascular dis-
ease, stroke, heart failure, atrial fibrillation, and left
ventricular hypertrophy. Data were collected for the
following microvascular complications: renal disease
(microalbuminuria, gross proteinuria, end-stage renal
disease), eye problems (background diabetic retinop-
athy, proliferative diabetic retinopathy, severe vision
loss, macular oedema, and cataract), foot ulcer (unin-
fected ulcer, infected ulcer, healed ulcer, and history of
amputation), and diabetic neuropathy. Data collected
on use of vascular disease preventative drugs included
use of renin-angiotensin system (RAS) blockers, aspirin
and statins.
Statistical analysis
The sample size calculation was based on the number of
patients (20,000) required to detect, with at least 95%
confidence, serious adverse drug reactions (SADRs) in-
cluding major hypoglycaemia events, with an incidence
of 15 events 100,000 (0.015%) for a single modern insu-
lin during the 6 months of the study. Assuming equal
distribution of patients among the three modern insu-
lins, the estimated sample size was 60,000 patients.
The influence of variables on vascular complications
was evaluated using a univariate logistical regression
model as a first step, run separately for macrovascular
and microvascular complications. Patient and disease
characteristics were included as variables in the model
if, based on the literature, they were considered to be
medically-related to vascular complications. These in-
cluded: geographic region, age, sex, diabetes duration,
BMI, HbA1c, FPG before breakfast, PPG after breakfast,
TC, TG, creatinine (microvascular complications model
only), HDL-C, LDL-C and SBP. Any significant correlates
from this univariate logistical regression were subse-
quently entered into a stepwise multivariate logistical re-
gression and only statistically significant correlates
remained in the model. The statistical significance level
employed was α = 0.05 (two tailed). P-values, odds ratio
(OR) and 95% confidence intervals (CIs) were calculated.
Results
Baseline patient characteristics
Baseline patient characteristics are summarised in Table 1.
Of the 66,726 patients enrolled in A1chieve: 17,806
had macrovascular complications and 38,670 had no
macrovascular complications at baseline; 35,078 had micro-
vascular complications and 21,190 had no microvascular
complications at baseline; and 18,420 had no macrovascular
or microvascular complications at baseline. South Asia had
the youngest patients with macrovascular complications(mean 56.3 years) and Latin America the oldest (mean
65.1 years). The Middle East had the youngest patients with
microvascular complications (mean 54.6 years) and Latin
America the oldest (mean 61.0 years; Table 1). The highest
BMI among patients with macrovascular complications was
recorded in Russia and the lowest in China (Table 1). The
same pattern was seen in patients with microvascular com-
plications, with the highest in Russia and the lowest in
China (Table 1). In patients with macrovascular complica-
tions, the longest mean diabetes duration was in Latin
America and North Africa and the shortest in South Asia.
Mean diabetes duration in patients with microvascular
complications was longest in Latin America and North
Africa and the shortest in South Asia (Table 1).
Metabolic control and QoL by geographical region
Baseline HbA1c and FPG values were similarly high across
the different regions and in patients with macrovascular
complications or microvascular complications (Table 2).
Mean baseline HbA1c values were ≥9.1% (≥76 mmol/mol)
in patients with macrovascular complications across all re-
gions and ≥9.4% (≥79 mmol/mol) across all regions in pa-
tients with microvascular complications. The baseline
data for other measurements related to metabolic control
and QoL are also displayed in Table 2.
Complications by geographical region
There were 17,806 patients with reported macrovascular
complications and 35,078 with microvascular compli-
cations (Table 3). Macrovascular complications were
reported in 27% of participants overall, with Russia having
the highest percentage (72%) and China the lowest (21%)
(Table 3). Microvascular complications were reported in
37 to 89% of participants, with Russia having the highest
percentage and South Asia the lowest. Neuropathy was
the highest reported microvascular complication in all re-
gions, ranging from 25% in South Asia to 83% in Russia.
Regression analysis
The univariate logistical regression revealed that all cor-
relates entered into both models were statistically signifi-
cant (all p < 0.05). Subsequently, all correlates were
entered into a stepwise multivariate logistical regression,
and only statistically significant association remained in
the models. After adjusting for regional differences, age,
BMI, diabetes duration, TC, TG, LDL-C and SBP were
positively correlated with macrovascular complications
(all p < 0.05; Figure 1a). Female gender, HDL-C, FPG and
HbA1c were negatively correlated with macrovascular
complications (all p < 0.05; Figure 1a). Age, BMI, diabetes
duration, HbA1c, LDL-C, creatinine, and SBP were posi-
tively correlated with microvascular complications (all
p < 0.01; Figure 1b). HDL-C levels were negatively corre-
lated with microvascular complications (p < 0.001; Figure 1b).
Table 1 Baseline patient characteristics by geographical region
All China South Asia East Asia North Africa Middle East Latin America Russia
All patients
Age, yr
n 65,381 10,889 21,775 9,966 4,011 14,549 1,126 3,065
mean (SD) 54.0 (12.0) 54.9 (14.7) 51.7 (10.2) 56.5 (12.1) 58.1 (11.8) 52.5 (11.4) 59.5 (12.9) 59.2 (9.2)
Sex
n 66,656 11,019 22,436 10,030 4,032 14,927 1,138 3,074
male (%) 37,033 (55.6) 6,300 (57.2) 13,908 (62.0) 5,092 (50.8) 1,717 (42.6) 8,636 (57.9) 485 (42.6) 895 (29.1)
BMI, kg/m2
n 59,115 10,817 19,292 8,664 3,611 12,571 1,092 3,068
mean (SD) 27.1 (5.0) 24.7 (3.4) 26.3 (3.8) 24.8 (4.3) 28.0 (5.0) 30.4 (5.5) 29.4 (5.6) 31.1 (5.3)
Diabetes duration, yr
n 65,786 10,814 22,316 9,776 4,016 14,658 1,135 3,071
mean (SD) 8.0 (6.2) 6.3 (6.3) 6.4 (4.7) 8.6 (6.9) 11.5 (7.2) 9.8 (6.0) 12.0 (8.3) 8.4 (5.4)
Patients with macrovascular complications
Age, yr
n 17,506 2,318 4,806 2,662 972 4,195 333 2,220
mean (SD) 59.3 (10.6) 61.7 (14.1) 56.3 (8.9) 61.5 (10.6) 63.6 (9.5) 57.7 (10.1) 65.1 (9.9) 61.0 (8.5)
Sex
n 17,786 2,342 4,943 2,684 978 4,278 335 2,226
male (%) 9,618 (54.1) 1,271 (54.3) 3,178 (64.3) 1,350 (50.3) 488 (49.9) 2,567 (60.0) 156 (46.6) 608 (27.3)
BMI, kg/m2
n 16,271 2,306 4,645 2,310 867 3,603 317 2,223
mean (SD) 27.9 (5.3) 25.1 (3.4) 26.2 (3.6) 25.3 (4.3) 28.8 (5.1) 31.1 (5.5) 30.4 (6.0) 31.6 (5.3)
Diabetes duration, yr
n 17,653 2,297 4,938 2,635 973 4,251 335 2,224
mean (SD) 10.3 (6.6) 9.4 (7.0) 8.4 (5.1) 10.5 (7.3) 14.2 (7.9) 12.4 (6.4) 14.6 (8.6) 9.2 (5.4)
Patients with microvascular complications
Age, yr
n 34,518 5,399 8,103 5,582 2,386 9,602 710 2,736
mean (SD) 56.9 (11.2) 57.9 (14.1) 54.8 (9.7) 59.0 (11.2) 60.9 (10.5) 54.6 (10.4) 61.0 (12.1) 59.8 (8.9)
Sex
n 35,033 5,467 8,288 5,614 2,395 9,810 715 2,744
male (%) 18,542 (52.9) 2,957 (54.1) 5,067 (61.1) 2,752 (49.0) 994 (41.5) 5,703 (58.1) 293 (41.0) 776 (28.3)
BMI, kg/m2
n 31,894 5,364 7,644 4,946 2,154 8,361 686 2,739
mean (SD) 27.6 (5.3) 24.7 (3.4) 26.1 (3.7) 25.0 (4.3) 28.4 (5.0) 30.9 (5.5) 29.4 (5.7) 31.2 (5.3)
Diabetes duration, yr
n 34,666 5,371 8,281 5,514 2,379 9,667 712 2,742
mean (SD) 9.9 (6.4) 8.4 (6.7) 8.2 (4.9) 10.4 (7.2) 13.6 (7.3) 11.2 (6.0) 13.7 (8.3) 8.9 (5.4)
Note: due to the observational nature of this study, not all baseline data were recorded.
BMI = body mass index.
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geographical region
Among participants with macrovascular complications
overall, 67% reported taking statins, while the proportionwas 56% among participants with microvascular compli-
cations. For participants with macrovascular complica-
tions and those with microvascular complications, the
highest statin use was in the Middle East (86% and 74%,
Table 2 Baseline metabolic control and quality of life by geographical region




n 12,727 1,332 4,002 1,170 620 3,426 147 2,030
mean (SD) 9.5 (1.7) 9.1 (2.1) 9.3 (1.2) 9.7 (2.0) 9.6 (1.8) 9.7 (1.7) 9.6 (2.4) 9.6 (1.7)
HbA1c, mmol/mol
n 12,727 1,332 4,002 1,170 620 3,426 147 2,030
mean (SD) 80.3 (18.6) 76.0 (23.0) 78.2 (13.1) 82.5 (21.9) 81.4 (19.7) 82.5 (18.6) 81.4 (26.2) 81.4 (18.6)
FPG before breakfast
n 13,603 1,859 4,064 1,431 715 3,143 204 2,187
mmol/l, mean (SD) 10.7 (3.3) 9.8 (3.6) 10.8 (2.8) 11.2 (4.2) 11.2 (4.2) 11.0 (3.3) 10.7 (4.2) 10.4 (2.6)
mg/dl, mean (SD) 192.8 (59.6) 176.5 (64.0) 194.2 (50.5) 202.4 (74.9) 201.3 (75.7) 198.0 (60.1) 191.9 (76.5) 187.7 (46.9)
PPG after breakfast
n 9,704 1,451 2,984 784 376 2,254 30 1,825
mmol/l, mean (SD) 14.5 (4.3) 14.0 (4.7) 15.3 (3.7) 15.4 (4.9) 14.7 (5.2) 15.4 (4.4) 13.1 (5.9) 12.2 (3.1)
mg/dl, mean (SD) 262.0 (77.0) 252.1 (85.4) 275.9 (65.9) 277.0 (87.6) 265.5 (94.0) 278.1 (78.9) 235.1 (105.6) 220.3 (55.6)
Total cholesterol, mmol/l
n 7,176 851 466 744 378 2,530 136 2,071
mean (SD) 5.5 (1.3) 5.1 (1.2) 5.2 (0.8) 5.3 (1.5) 4.6 (1.3) 5.4 (1.2) 5.6 (1.7) 6.1 (1.3)
Triglycerides, mmol/l
n 6,732 844 703 637 402 2,524 116 1,506
mean (SD) 2.1 (1.0) 2.0 (1.3) 2.2 (0.7) 2.0 (1.0) 1.6 (0.9) 2.3 (1.0) 2.4 (1.2) 2.1 (1.0)
Creatinine, μmol/l
n 6,865 724 776 627 350 2,370 103 1,915
mean (SD) 87.7 (32.9) 48.7 (43.6) 96.2 (30.3) 97.6 (35.1) 89.5 (29.6) 95.7 (29.4) 94.5 (28.6) 85.2 (19.5)
HDL-C, mmol/l
n 5,602 777 714 539 255 2,283 98 936
mean (SD) 1.1 (0.4) 1.2 (0.4) 1.0 (0.2) 1.2 (0.5) 1.1 (0.4) 1.0 (0.3) 1.0 (0.3) 1.4 (0.6)
LDL-C, mmol/l
n 5,711 794 713 545 238 2,364 94 963
mean (SD) 3.2 (1.1) 3.0 (1.0) 3.4 (1.0) 3.4 (1.3) 2.8 (1.4) 3.2 (1.0) 3.2 (1.1) 3.4 (1.2)
SBP, mmHg
n 13,744 1,552 3,376 1,969 755 3,619 274 2,199
mean (SD) 141.0 (19.5) 137.2 (18.3) 145.2 (21.0) 133.3 (18.7) 137.8 (20.0) 141.4 (18.9) 131.8 (16.5) 145.7 (16.5)
QoL*
n 11,329 1,712 3,611 2,156 676 865 261 2,048




n 24,352 3,128 6,673 2,385 1,545 7,726 378 2,517
mean (SD) 9.6 (1.7) 9.4 (2.3) 9.4 (1.3) 9.7 (2.0) 9.5 (1.8) 9.7 (1.7) 10.1 (2.2) 9.6 (1.7)
HbA1c, mmol/mol
n 24,352 3,128 6,673 2,385 1,545 7,726 378 2,517
mean (SD) 81.4 (18.6) 79.2 (25.1) 79.2 (14.2) 82.5 (21.9) 80.3 (19.7) 82.5 (18.6) 86.9 (24.0) 81.4 (18.6)
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Table 2 Baseline metabolic control and quality of life by geographical region (Continued)
FPG before breakfast
n 25,986 4,239 6,655 3,015 1,744 7,162 480 2,691
mmol/l, mean (SD) 10.8 (3.5) 10.0 (3.5) 10.7 (3.0) 11.3 (4.2) 11.1 (4.1) 11.2 (3.5) 11.7 (4.6) 10.4 (2.7)
mg/dl, mean (SD) 194.5 (62.9) 179.4 (63.6) 193.3 (54.3) 202.8 (75.5) 200.4 (74.5) 201.5 (62.4) 210.5 (83.3) 186.9 (47.7)
PPG after breakfast
n 18,300 3,297 4,762 1,657 1,025 5,183 110 2,266
mmol/l, mean (SD) 14.8 (4.5) 13.8 (4.8) 15.5 (3.9) 15.6 (5.0) 14.8 (4.7) 15.5 (4.4) 15.6 (6.0) 12.1 (3.0)
mg/dl, mean (SD) 265.8 (80.3) 249.4 (86.7) 279.0 (69.7) 281.5 (89.3) 265.7 (84.6) 279.6 (80.1) 281.4 (107.3) 218.3 (54.9)
Total cholesterol, mmol/l
n 13,795 2,005 812 1,509 993 5,590 334 2,552
mean (SD) 5.4 (1.3) 5.1 (1.3) 5.1 (0.8) 5.3 (1.4) 4.7 (1.3) 5.3 (1.2) 5.8 (1.6) 6.0 (1.3)
Triglycerides, mmol/l
n 13,356 1,970 1,371 1,257 1,030 5,572 290 1,866
mean (SD) 2.1 (1.1) 2.1 (1.3) 2.1 (0.8) 2.0 (1.1) 1.6 (0.9) 2.2 (1.0) 2.5 (1.3) 2.1 (1.0)
Creatinine, μmol/l
n 13,399 1,779 1,482 1,185 893 5,440 261 2,359
mean (SD) 83.5 (32.7) 52.3 (42.3) 89.9 (27.9) 95.8 (37.9) 85.0 (28.2) 88.2 (28.6) 89.2 (26.4) 84.8 (19.1)
HDL-C, mmol/l
n 11,472 1,823 1,398 1,083 678 5,067 234 1,189
mean (SD) 1.1 (0.4) 1.2 (0.4) 1.0 (0.2) 1.2 (0.4) 1.1 (0.4) 1.1 (0.3) 1.0 (0.3) 1.4 (0.6)
LDL-C, mmol/l
n 11,580 1,852 1,379 1,090 646 5,185 217 1,211
mean (SD) 3.2 (1.1) 3.1 (1.1) 3.1 (0.9) 3.2 (1.2) 2.9 (1.4) 3.2 (1.0) 3.2 (1.1) 3.3 (1.1)
SBP, mmHg
n 26,661 3,487 5,656 4,022 1,899 8,282 614 2,701
mean (SD) 137.3 (18.7) 134.9 (17.5) 141.4 (21.0) 132.0 (17.9) 135.2 (18.8) 137.1 (17.4) 131.5 (17.2) 143.1 (16.8)
QoL*
n 21,166 3,947 6,103 4,489 1,741 1,805 555 2,526
mean (SD) 62.3 (16.9) 75.2 (13.8) 52.8 (11.1) 67.9 (16.0) 61.1 (17.5) 64.1 (15.5) 64.8 (18.3) 54.3 (17.0)
Note: due to the observational nature of this study, not all baseline data were recorded.
*EQ-5D™ (100 = best imaginable health; 0 = worst imaginable health) [20].
Table 3 Baseline patient complications by geographical region
All China South Asia East Asia North Africa Middle East Latin America Russia
Patients with macrovascular
complications, n (%)
17,806 (27.2) 2,342 (21.3) 4,946 (23.3) 2,685 (26.8) 979 (24.2) 4,293 (28.7) 335 (29.4) 2,226 (72.4)
Patients with microvascular
complications, n (%)
35,078 (53.5) 5,467 (49.6) 8,293 (39.0) 5,615 (56.0) 2,397 (59.4) 9,847 (65.8) 715 (62.8) 2,744 (89.3)
Renal disease, n (%) 18,271 (27.9) 2,455 (22.3) 4,321 (20.3) 2,845 (28.4) 1,077 (26.7) 6,108 (40.8) 376 (33.0) 1,089 (35.4)
Eye problems, n (%) 17,198 (26.3) 2,430 (22.1) 3,464 (16.3) 2,380 (23.7) 1,354 (33.5) 5,081 (33.9) 368 (32.3) 2,121 (69.0)
Foot ulcer, n (%) 3,538 (5.4) 274 (2.5) 1,046 (4.9) 536 (5.3) 147 (3.6) 1,289 (8.6) 85 (7.5) 161 (5.2)
Neuropathy, n (%) 25,179 (38.4) 3,671 (33.3) 5,234 (24.6) 3,706 (36.9) 1,530 (37.9) 7,995 (53.4) 491 (43.1) 2,552 (83.0)
Note: due to the observational nature of this study, not all baseline data were recorded.
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Figure 1 Complication predictor analysis. a) Macrovascular complications. b) Microvascular complications. OR = odds ratio; CI = confidence interval.
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respectively). Use of vascular disease preventative drugs
was higher among participants with macrovascular com-
plications (statins 67%, aspirin 79%, RAS blocker 78%)
than those with microvascular complications (statins
56%, aspirin 64%, RAS blocker 63%) (Table 4).
In all regions, aspirin use was higher in participants
with macrovascular complications than those with
microvascular complications (Table 4). In addition, as-
pirin use was higher than statin use in all regions ex-
cept East Asia, where usage levels of the two drugs
were similar among participants with macrovascular
complications, and statin use was higher than aspirin
use among participants with microvascular complica-
tions (Table 4).
A higher proportion of participants with macro-
vascular complications used a RAS blocker than those
with microvascular complications in all regions apart
from Russia, where usage was similar for the two groups.
Russia also had the highest use of RAS blocker, both
among participants with macrovascular complications
(93%) and those with microvascular complications
(87%). In contrast, use of RAS blocker was lowest in
China for both participant groups (56% of participants
with macrovascular complications and 42% of partici-
pants with microvascular complications).
Discussion
Baseline HbA1c was high across all geographical regions,
and vascular complication rates were generally high. In
addition, the use of vascular protective therapies, even
in those patients with vascular complications, was sub-
optimal. The particularly low reported use of vascular
protective therapies in patients from China is commen-
surate with previous findings [21]. The findings suggest
poor glycaemic control and suboptimal diabetes man-
agement across many geographical regions, which may
be due to poor adherence to treatment regimens, lackTable 4 Use of vascular disease preventative drugs by geogra
All China South Asia E
Patients with macrovascular
complications
RAS blocker, n (%) 13,910 (78.1) 1,303 (55.6) 3,771 (76.3) 1,9
Aspirin, n (%) 13,995 (78.6) 1,644 (70.2) 3,784 (76.6) 1,8
Statins, n (%) 11,958 (67.2) 1,139 (48.6) 3,057 (61.9) 1,8
Patients with microvascular
complications
RAS blocker, n (%) 21,884 (62.6) 2,268 (41.5) 4,792 (58.5) 3,4
Aspirin, n (%) 22,207 (63.5) 2,704 (49.5) 4,958 (60.6) 2,6
Statins, n (%) 19,709 (56.4) 1,856 (33.9) 4,325 (52.8) 3,1
Note: due to the observational nature of this study, not all baseline data were recor
RAS = renin-angiotensin system.of access to therapy, poor diet, and delay in initiating,
or failure to adequately optimise, insulin therapy
[12-14,16,22]. For example, significant numbers of
people with diabetes have poor psychological well-
being and these psychological problems can adversely
affect adherence to treatment [22]. Some of the variation
seen in the prevalence of complications in different geo-
graphical regions may have been due to variations in clin-
ical care, healthcare resources, diagnostic criteria, and
definitions used in routine clinical practice, among other
reasons. In particular, the high rates of complications
among participants from Russia may have been due to
a variety of factors, such as late diagnoses of diabetes,
late initiation of treatment, or lifestyle factors. Without
large-scale epidemiological studies, it is difficult to as-
certain the extent to which clinical practice may impact
on the rate of complications in people with diabetes in
Russia or other regions.
Results of the correlation analysis revealed relation-
ships between vascular complications and various disease
characteristics. Age, BMI, diabetes duration, LDL-C,
and SBP were positively associated with macrovascular
and microvascular complications, while TC and TG
were positively correlated with macrovascular complica-
tions and creatinine with microvascular complications.
These findings are consistent with the large evidence
base showing that the risk of developing these compli-
cations is positively associated with these variables
[23-27]. The negative association between HDL-C val-
ues and macrovascular and microvascular complica-
tions would also be expected given the documented
inverse relationship between blood levels of HDL-C and
cardiovascular disease risk [28]. The profile of cholesterol
levels is important in people with type 2 diabetes as it
reflects atherogenic dyslipidaemia, which is characterised
by small dense LDL-C, low HDL-C and high TG levels
[29]. Regarding the result suggesting female gender
was associated with a lower frequency of macrovascularphical region
ast Asia North Africa Middle East Latin America Russia
92 (74.2) 778 (79.5) 3,719 (86.6) 285 (85.1) 2,062 (92.6)
66 (69.5) 801 (81.8) 3,973 (92.5) 252 (75.2) 1,675 (75.2)
46 (68.8) 715 (73.0) 3,710 (86.4) 189 (56.4) 1,302 (58.5)
65 (61.7) 1,557 (65.0) 6,907 (70.1) 499 (69.8) 2,396 (87.3)
98 (48.0) 1,598 (66.7) 7,922 (80.5) 427 (59.7) 1,900 (69.2)
33 (55.8) 1,288 (53.7) 7,323 (74.4) 312 (43.6) 1,472 (53.6)
ded.
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results [30-32].
In contrast, the finding that HbA1c and FPG values were
negatively associated with establishment of macrovascular
complications was surprising. The correlation coefficient
between HbA1c and FPG values was r = 0.44, and there-
fore, colineairty is not likely to have distorted the model
and explain this finding. One possible explanation for this
surprising result is the study design. The A1chieve study
was a cross-sectional study and as such, the present base-
line HbA1c and FPG values were used to predict the estab-
lishment of diabetes complications which had developed
over the course of the disease. However, there may not be
a clear association between the present value and the
value several years prior to this. In addition, complications
(especially macrovascular complications) usually take sev-
eral years to develop in the presence of high HbA1c levels,
and so an association would become apparent in a cohort
study rather than a cross-sectional study. The temporal
relationships between HbA1c levels and establishment of
macrovascular and/or microvascular complications must
be further established before fully understanding the
power of current HbA1c levels to predict complications.
Alternative explanations for this unusual finding could
be the fact that the study population included a very
heterogenous group ranging across four continents,
leading to genetic variability, dietary variability and risk
factor variability. Minimising these confounding factors
may have provided a clearer picture of the relationships
between the various disease parameters and vascular
complications and this could be an area for future re-
search. In addition, there were no specific or defined
measurements of the macrovascular and microvascular
complications reported in this study, and these were
classified based on clinical judgement of the physicians.
Other limitations of this observational study include po-
tential bias and lack of a control group; however, an ad-
vantage of this observational study was that it had less
stringent inclusion and exclusion criteria, allowing very
large numbers of people to be assessed in many different
geographical regions, something that is virtually impos-
sible with randomised controlled trials.
Conclusions
Across all the geographical regions, patients showed
poor glycaemic control at the point of commencing on
insulin analogues, vascular complication rates were gen-
erally high, and use of vascular disease preventative ther-
apies was generally sub-optimal. Many of the disease
characteristics were statistically significantly associated
with macrovascular and/or microvascular complications
at baseline. These findings suggest that suboptimal dia-
betes therapy is contributing to the burden of type 2 dia-
betes worldwide. Closer adherence to diabetes guidelines,which may include earlier initiation and optimisation
of insulin regimens (e.g., with insulin analogues in the
A1chieve population), may reduce the prevalence of vascu-
lar complications, improve the lives of people with dia-
betes and reduce the burden on healthcare systems.
Consent
Participants gave written informed consent for the re-
sults of the study to be published in a scientific or med-
ical journal.
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